"Kerala CM Inaugurates Agappe Diagnostics' New Manufacturing Unit"

Kerala Chief Minister Pinarayi Vijayan inaugurated Agappe Diagnostics Ltd.'s new 100,000 sq ft manufacturing facility at Infopark on Thursday. Agappe Diagnostics, a leading name in the In Vitro Diagnostics (IVD) sector, has expanded its operations with this state-of-the-art plant.

In his speech, Chief Minister Vijayan highlighted Kerala’s evolving industrial landscape, noting its recent recognition as the top state in India for ease of doing business. He emphasized Kerala’s role in attracting significant investments and fostering innovation.

During the inauguration, the Chief Minister also unveiled the first "Make in India" In-Vitro Biomarkers using CLEIA (Chemiluminescent Enzyme Immunoassay) technology. This diagnostic equipment, developed in collaboration with Japan’s Fujirebio Holdings Inc., represents a significant advancement in diagnostic technology.

Agappe Diagnostics, celebrating 29 years of excellence, serves 75,000 customers across 90 countries. The company aims to provide advanced diagnostic technology at affordable prices, enhancing accessibility for the general public.

State Industries Minister P. Rajeeve praised Kerala’s medical devices industry, which, despite constituting only 6% of the national sector, contributes 20% of its total turnover. This achievement is significant given Kerala's relatively small size, representing just 1.2% of India's land area and housing 2.8% of its population.

Thomas John, Managing Director of Agappe Diagnostics, noted that the new facility complements the company's existing reagent unit in Pattimattom and its first equipment manufacturing unit at Kinfra, Nellad. The expansion is expected to create local employment opportunities and elevate the standard of equipment manufacturing.

The new diagnostic tools are designed to aid in the early detection of critical diseases, including Alzheimer’s, cancer, and gastrointestinal disorders. CLEIA technology enhances the screening, monitoring, and personalized treatment of these conditions, potentially improving patient outcomes and survival rates.

HBL